Tykerb®, lapatinib, is used to treat certain types of breast cancer (HER2-overexpressing) which have spread beyond the original tumour or to other organs (advanced or metastatic breast cancer). It may slow or stop cancer cells from growing, or may kill them.
Tykerb is given in combination with other anticancer medicines.
Tykerb is given in combination with capecitabine, for patients who have had treatment for advanced or metastatic breast
cancer before. This previous treatment for the metastatic breast cancer must have included an anthracycline, a taxane and trastuzumab.
Tykerb is given in combination with letrozole, for postmenopausal women with hormone receptor positive metastatic breast cancer that overexpress HER2 and who are candidates for hormonal therapy.